Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma
暂无分享,去创建一个
E. Tsai | J. Suen | M. Sung | P. Chiang | Shun-Chen Huang | Chien‐Hsu Chen | Ping-Chia Chiang | Mu-Yao Tsai
[1] E. Tsai,et al. Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma , 2021, Cancer Immunology, Immunotherapy.
[2] J. Pow-Sang,et al. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study , 2020, World Journal of Urology.
[3] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.
[4] C. Ohyama,et al. Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan‐Japan UTUC Collaboration Cohort , 2020, International journal of urology : official journal of the Japanese Urological Association.
[5] Y. Lotan,et al. Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. , 2019, Urologic oncology.
[6] Qiaochao Chen,et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis , 2019, Cancer management and research.
[7] H. Kume,et al. The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count , 2018, Cancer medicine.
[8] K. Bensalah,et al. Prognostic Value of PD‐1 and PD‐L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma , 2017, The Journal of urology.
[9] Hong Zhang,et al. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma , 2017, Medical Oncology.
[10] J. Lunceford,et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.
[11] A. Chinnaiyan,et al. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. , 2016, European urology focus.
[12] N. Lawrentschuk,et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review , 2017, World Journal of Urology.
[13] Chin-Li Lu,et al. Chronic kidney disease is associated with upper tract urothelial carcinoma – A nationwide population-based cohort study in Taiwan , 2016 .
[14] Shengjie Liu,et al. Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. , 2015, Japanese journal of clinical oncology.
[15] K. Bensalah,et al. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. , 2015, The Journal of urology.
[16] Jing-Shiang Hwang,et al. Increased Upper and Lower Tract Urothelial Carcinoma in Patients with End-Stage Renal Disease: A Nationwide Cohort Study in Taiwan during 1997–2008 , 2014, BioMed research international.
[17] Y. Lotan,et al. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. , 2014, The Journal of urology.
[18] C. Shun,et al. Aristolochic acid‐induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes , 2013, International journal of cancer.
[19] Felicia Wu,et al. Risk Assessment of Upper Tract Urothelial Carcinoma Related to Aristolochic Acid , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[20] Pau-Chung Chen,et al. Increased risks of upper tract urothelial carcinoma in male and female chinese herbalists. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.
[21] J. W. Lee,et al. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. , 2010, Urology.
[22] F. Montorsi,et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. , 2010, The Journal of urology.
[23] U. Capitanio,et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.
[24] H. Kuo,et al. Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.
[25] Y. Lotan,et al. Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.
[26] T. Igarashi,et al. The prognostic value of p53, Ki‐67 and matrix metalloproteinases MMP‐2 and MMP‐9 in transitional cell carcinoma of the renal pelvis and ureter , 2005, International journal of urology : official journal of the Japanese Urological Association.
[27] Jin-Hwang Liu,et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. , 2002, Urology.
[28] Y. H. Lee,et al. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. , 2000, The Journal of urology.